Vertex’s Exa-Cel Off-Target Analyses Set Early Bar For Other Genome Editing Products

 
• By Sue Sutter
Foggy road
FDA's guidance is foggy on the quantum of evidence needed for nonclinical off-target analyses. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers